Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l

Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Ridker, 1999, Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators, Circulation, 100, 230, 10.1161/01.CIR.100.3.230 Albert, 2001, Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study, JAMA, 286, 64, 10.1001/jama.286.1.64 Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601 Jialal, 2001, Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels, Circulation, 103, 1933, 10.1161/01.CIR.103.15.1933 Ridker, 1998, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events (CARE) Investigators, Circulation, 98, 839, 10.1161/01.CIR.98.9.839 Ridker, 2005, C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, 20, 10.1056/NEJMoa042378 Cannon, 2004, Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Milani, 2004, Reduction in C-reactive protein through cardiac rehabilitation and exercise training, J Am Coll Cardiol, 43, 1056, 10.1016/j.jacc.2003.10.041 de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307 Ballantyne, 2003, Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia, Circulation, 107, 2409, 10.1161/01.CIR.0000068312.21969.C8 Despres, 2003, Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome, Arterioscler Thromb Vasc Biol, 23, 702, 10.1161/01.ATV.0000062990.62034.64 Haffner, 2002, Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, Circulation, 106, 679, 10.1161/01.CIR.0000025403.20953.23 Ridker, 2003, Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein, Circulation, 108, 2292, 10.1161/01.CIR.0000100688.17280.E6